Adenocarcinoma — Trials

Adenocarcinoma — Trials · CancerIndex

Clinical trials

Registered studies

9,703 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 2,753
Recruiting: 1,520
Ph III recruiting: 168
Growth YoY: +6.8%
Industry share: 23%
Top sponsor: National Cancer Institute (NCI)
Termination share: 36.5%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (1,319)

clinicaltrialsPublishedShowing 1,251–1,300 of 1,435 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05920863	Lenvatinib Combined with Tislelizumab and TACE Applied As Neoadjuvant Regimen for the Patients of CNLC Stage IB and IIA Hepatocellular Carcinoma with High-risk Recurrence Factors	recruiting	Phase 2	35	Zhejiang Cancer HospitalOTHER	1	Feb 11, 2025	clinicaltrials
NCT06671262	Neoadjuvant Toripalimab and Radiotherapy Treatment in N+ HR+ Breast Cancer(NEOTRIO-HR)	recruiting	Phase 2	74	Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER